Sensei Biotherapeutics, Inc. (SNSE): Price and Financial Metrics
GET POWR RATINGS... FREE!
SNSE Stock Price Chart Interactive Chart >
SNSE Price/Volume Stats
| Current price | $1.81 | 52-week high | $13.00 |
| Prev. close | $1.70 | 52-week low | $1.45 |
| Day low | $1.70 | Volume | 48,400 |
| Day high | $1.85 | Avg. volume | 83,496 |
| 50-day MA | $1.92 | Dividend yield | N/A |
| 200-day MA | $5.74 | Market Cap | 55.44M |
Sensei Biotherapeutics, Inc. (SNSE) Company Bio
Sensei Biotherapeutics, Inc. operates as a clinical-stage immunotherapy company. The Company focuses in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. Sensei Biotherapeutics serves customers in the United States.
Latest SNSE News From Around the Web
Below are the latest news stories about Sensei Biotherapeutics Inc that investors may wish to consider to help them evaluate SNSE as an investment opportunity.
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) insiders placed bullish bets worth US$1.0m in the last 12 monthsWhen a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... |
Sensei Biotherapeutics names Erin Colgan as CFONo summary available. |
Sensei Biotherapeutics Announces Executive PromotionsCompany names Erin Colgan as chief financial officer and Robert Pierce, M.D. as chief R&D officerBOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced two key promotions within the company’s senior management team. Erin Colgan, formerly senior vice president of finance and administration, has been appointed to chief financial officer. Robe |
Sensei Biotherapeutics Named a Winner of Comparablys Best CEO AwardBOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it has won a Comparably award for 2021 Best CEOs. |
Sensei Biotherapeutics Named a Winner of Comparably’s Best CEO AwardBOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it has won a Comparably award for 2021 “Best CEOs.” “What makes Comparably awards so meaningful is that they are based exclusively on employee feedback,” said Elisabeth Colunio, Vice President of Human Resources. “We are thrilled but not surprised to see John recognized as a 2021 B |
SNSE Price Returns
| 1-mo | 16.77% |
| 3-mo | -49.86% |
| 6-mo | -73.69% |
| 1-year | -85.44% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -68.79% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...